ABSTRACT
Objective. To ascertain if parents are familiar with current recommendations on pediatric vision screening and to assess their knowledge of the roles that pediatricians, ophthalmologists and optometrists have in this screening process. Methods. A survey was targeted at parents to determine what the general public understands regarding vision screening. Results. The survey was conducted from January-May 2010. One hundred fifty six persons responded. Over one-third did not know the difference between eye care specialists. Many believed opticians and optometrists receive medical school training. Over forty percent incorrectly identified the recommended visual acuity testing age. A large discrepancy existed regarding who should perform pediatric eye exams. Most agreed a failed screening warranted follow-up, but there was not a uniform opinion as to when to seek care. The majority of respondents understood amblyopia should be treated at least before age ten; although nine percent believed amblyopia could be treated at any age. Discussion. There is a significant lack of understanding of the current screening recommendations, difference between eye care professionals, and the importance of early treatment of amblyopia. Conclusions. Many parents do not understand the potential detrimental consequences of delayed care in the event their child fails a vision screening.
ABSTRACT
PURPOSE: To assess the overall and progression-free survival, response rate, and toxicity of combined docetaxel and celecoxib in the treatment of patients with non-small cell lung cancer progressing after initial chemotherapy for advanced disease. PATIENTS AND METHODS: Patients with non-small cell lung cancer and either measurable or evaluable disease experiencing progression after one or more platinum-based chemotherapy regimens given for advanced or metastatic disease, ECOG performance status 0-2, and adequate hematologic and biochemistry parameters were eligible for study inclusion; exclusion criteria included symptomatic brain metastases and full dose anti-coagulation. Therapy consisted of docetaxel 75 mg/m(2) every 21 days for a maximum of six cycles and celecoxib 400 mg orally twice daily commencing 7 days prior to docetaxel and continuing until disease progression. RESULTS: A total of 41 patients were enrolled of whom 39 were deemed eligible and received at least one course of docetaxel. The mean age of enrolled patients was 60.5 years (range, 44-77); 67% were men and 79% white. All but one patient had an Eastern Clinical Oncology Group (ECOG) performance status of 0 or 1. Most (72%) had been treated with a prior taxane. Overall survival was 11.3 months (95% confidence interval [CI]: 7.9, 15.7) and progression-free survival 19.6 weeks (95% CI: 13.5, 25.0). A response rate of 10.2% (95% CI: 3%, 24%) for all eligible and treated patients was found. Grade 3 or 4 neutropenia occurred in 10/39 patients (25.6%); one death due to neutropenic sepsis occurred. No grade 3 or 4 renal or hepatic toxicities were documented. CONCLUSION: Treatment with combination celecoxib and docetaxel is a safe regimen with a toxicity profile similar to that of docetaxel alone. Survival data are encouraging compared to historical controls and may prolong time to disease progression compared with single-agent docetaxel.
